Evidence map›Paper›PMID 42760872›Full record

ArticleJournal of clinical pharmacology2026

Prospective Evaluation of Thiotepa Pharmacokinetics in Children and Young Adults Undergoing Allogeneic or Autologous Hematopoietic Cell Transplantation.

Jordan Brooks, Shams Ismaeil, Maria-Stephanie Hughes, Beth Apsel-Winger, Ying Lu, Liusheng Huang, Christine Higham, Kristina Nelson, Susie Long, Ashish Gupta and 7 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Jordan BrooksInsightRX, San Francisco, CA, USA.ORCID https://orcid.org/0000-0001-9060-9714
Shams IsmaeilCenter for Translational Medicine, University of Maryland, MD, USA.ORCID https://orcid.org/0009-0009-6289-703X
Maria-Stephanie HughesInsightRX, San Francisco, CA, USA.ORCID https://orcid.org/0009-0009-7563-9881
Beth Apsel-WingerDepartment of Clinical Pharmacy, University of California San Francisco, San Francisco, CA, USA.ORCID https://orcid.org/0000-0002-6909-8072
Ying LuDepartment of Pediatrics, Division of Allergy, Immunology, and Bone Marrow Transplantation, University of California San Francisco, San Francisco, CA, USA.
Liusheng HuangDepartment of Clinical Pharmacy, University of California San Francisco, San Francisco, CA, USA.ORCID https://orcid.org/0000-0003-2702-4486
Christine HighamDepartment of Pediatrics, Division of Allergy, Immunology, and Bone Marrow Transplantation, University of California San Francisco, San Francisco, CA, USA.ORCID https://orcid.org/0000-0002-4618-3813
Kristina NelsonUniversity of Minnesota Masonic Children's Hospital, University of Minnesota, Minneapolis, MN, USA.ORCID https://orcid.org/0009-0003-5969-4078
Susie LongUniversity of Minnesota Masonic Children's Hospital, University of Minnesota, Minneapolis, MN, USA.ORCID https://orcid.org/0000-0002-2730-451X
Ashish GuptaUniversity of Minnesota Masonic Children's Hospital, University of Minnesota, Minneapolis, MN, USA.ORCID https://orcid.org/0000-0001-5679-5533
Nahal Rose LalefarDepartment of Pediatrics, University of California Davis, Davis, CA, USA.
Eric AndersonRady Children's Hospital of San Diego, San Diego, CA, USA.ORCID https://orcid.org/0000-0003-3665-3102
Michael A PulsipherDivision of Pediatric Hematology and Oncology, Intermountain Primary Children's Hospital, Huntsman Cancer Institute, Spencer Fox Eccles School of Medicine and the University of Utah, Salt Lake City, Utah, USA.ORCID https://orcid.org/0000-0003-3030-8420
Sung-Yun PaiNational Cancer Institute, Bethesda, MD, USA.ORCID https://orcid.org/0000-0002-0158-8147
Ron J KeizerInsightRX, San Francisco, CA, USA.
Christopher C DvorakDepartment of Pediatrics, Division of Allergy, Immunology, and Bone Marrow Transplantation, University of California San Francisco, San Francisco, CA, USA.
Janel Long-BoyleDepartment of Clinical Pharmacy, University of California San Francisco, San Francisco, CA, USA.ORCID https://orcid.org/0009-0002-5545-2808

Funding

National Center for Advancing Translational Sciences and National Institutes of Health ULTR001872National Institute of Allergy and Infectious Diseases U01A1 126612National Institute of Allergy and Infectious Diseases U01A1 184132NCI NIH HHS P30CA040214
6 · The paper itself

Abstract

Thiotepa (TT) is often included in high-dose chemotherapy prior to hematopoietic cell transplantation (HCT); however, exposure-response relationships of TT and its primary metabolite, N,N',N''-triethylenethiophosphoramide (TEPA), remain undefined. This was a prospective study enrolling children and young adults undergoing autologous and allogeneic HCT from multiple centers. Time-concentration data were modeled using nonlinear mixed effects modeling along with clinical covariates potentially impacting pharmacokinetics. Cumulative area-under-the-curve (cAUC) for TT and TEPA were derived using post hoc individual estimates for clearance. The combined cAUC

Indexed as

Antineoplastic Agents, AlkylatingHematopoietic Stem Cell TransplantationThiotepaAdolescentArea Under CurveChildChild, PreschoolFemaleHumansInfantMaleModels, BiologicalProspective StudiesTransplantation, AutologousTransplantation, HomologousYoung AdultAntineoplastic Agents, AlkylatingThiotepahematopoietic cell transplantationpediatricpopulation pharmacokineticsthiotepa

Identifiers

PMID42760872
PMCPMC13589261

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.